Purple Biotech PPBT 深 滬
交易中 08-10 09:54:15 美东时间
1.4354
+0.005
+0.38%
華盛通- 最 高1.52
- 今 開1.52
- 成交量 83.51万股
- 最 低 1.4354
- 昨 收 1.43
- 總市值 133.82万
- 52周最高 24.00
- 市盈率 靜 --
- 換手率 89.58%
- 52周最低 1.16
- 委 比 -53.85%
- 總股本 93.23万
- 歷史最高 13900.00
- 量 比 811.95
- 振 幅 5.92%
- 歷史最低 1.4354
- 每 手 1
- 風險率 4.94%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 花旗下调美光科技目标价从1400美元降至1150美元；爱彼迎、Datadog、Cloudflare、Etsy、Natera、拉夫劳伦获多家大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持InflaRx"超配"评级，目标价从4美元升至6美元；RBC Capital：维持Nuvation Bio"跑赢大市"评级，目标价从19美元升至20美元
今天 19:24
HC Wainwright & Co. Maintains Buy on Purple Biotech, Lowers Price Target to $17
HC Wainwright & Co. analyst Emily Bodnar maintains Purple Biotech (NASDAQ:PPBT) with a Buy and lowers the price target from $30 to $17.
08-08 02:10
Purple Biotech Q2 EPS $(0.35) Beats $(0.98) Estimate
Purple Biotech (NASDAQ:PPBT) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.98) by 64.29 percent. This is a 91.25 percent increase over losses of $(4.00) per share from the same period last year.
08-07 19:07
Purple Biotech Presents New Cancer Immunotherapy Data at EACR 2026, Says IM1240 Data Support First Human Study in 2027
Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage oncology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced the presentation of new preclinical data from its lea...
06-11 19:06
Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window
Purple Biotech's IM1240, a CAPTN-3 platform candidate, showed superior pharmacokinetics and safety in non-human primate studies, with an 8-fold longer half-life and 16-fold greater exposure than the non-capped variant. It demonstrated anti-tumor activity in PD-1- and chemotherapy-resistant cancers, including head and neck, bladder, and lung cancers, with the NKG2A arm playing a key role. IM1240 induced immune structures linked to effective anti-t...
06-11 11:00
Purple Biotech Files $200M Mixed Securities Shelf
https://www.sec.gov/Archives/edgar/data/1614744/000121390026059665/ea0291624-f3_purple.htm
05-21 05:43
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Silexion Therapeutics (NASDAQ:SLXN) shares moved upwards by 147.2% to ...
05-20 20:06
Earnings Scheduled For May 15, 2026
Companies Reporting Before The Bell • Traws Pharma (NASDAQ:TRAW) is expected to...
05-15 19:11
Purple Biotech GAAP EPS of -$0.09
Purple Biotech press release (PPBT): Q1 GAAP EPS of -$0.09. Adjusted Net Loss (as reconciled below) for the three months ended March 31, 2026, was $2.1 million, an increase of $0.8 million, compared t...
05-15 19:08
Purple Biotech Q1 EPS $0.09 Beats $(1.06) Estimate
Purple Biotech (NASDAQ:PPBT) reported quarterly earnings of $0.09 per share which beat the analyst consensus estimate of $(1.06) by 108.49 percent. This is a 105.29 percent increase over losses of $(1.70) per share from
05-15 19:07
